Safety Evaluation of Natural Drugs in Chronic Skeletal Disorders: A Literature Review of Clinical Trials in the Past 20 years

Zhou, Dongyang; Zhang, Hao; Xue, Xu; Tao, Yunxia; Wang, Sicheng; Ren, Xiaoxiang; Su, Jiacan

doi:10.3389/fphar.2021.801287

Cited by 16 publications

(15 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NSAIDs are the most widely used drugs that diminish the production of inflammatory factors and exert analgesic effects 52 . However, NSAIDs have gastrointestinal, neurological, hematologic and allergic side effects, as well as symptomatic treatment and relief of patient suffering, but not slowing down the progression of the disease 53 , 54 . Another group of drugs can significantly relieve the clinical symptoms of OA is glucocorticoids, which have a potent anti-inflammatory effect and can suppress the proliferation of aberrant tissues and reduce joint effusion, thus achieving a significant effect of detumescence and analgesia 55 .…”

Section: Physiopathology Of Osteoarthritismentioning

confidence: 99%

Targeted and responsive biomaterials in osteoarthritis

Li¹,

Zhang²,

Han³

et al. 2023

Theranostics

View full text Add to dashboard Cite

Osteoarthritis (OA) is a degenerative disease characterized by loss of articular cartilage and chronic inflammation, involving multiple cellular dysfunctions and tissue lesions. The non-vascular environment and dense cartilage matrix in the joints tend to block drug penetration, resulting in low drug bioavailability. There is a desire to develop safer and more effective OA therapies to meet the challenges of an aging world population in the future. Biomaterials have achieved satisfactory results in improving drug targeting, prolonging the duration of action, and achieving precision therapy. This article reviews the current basic understanding of the pathological mechanisms and clinical treatment dilemmas of OA, summarizes and discusses the advances for different kinds of targeted and responsive biomaterials in OA, seeking to provide new perspectives for the treatment of OA. Subsequently, limitations and challenges in clinical translation and biosafety are analyzed to guide the development of future therapeutic strategies for OA. As the need for precision medicine rises over time, emerging multifunctional biomaterials based on tissue targeting and controlled release will become an irreplaceable part of OA management.

show abstract

Section: Physiopathology Of Osteoarthritismentioning

confidence: 99%

Targeted and responsive biomaterials in osteoarthritis

Li¹,

Zhang²,

Han³

et al. 2023

Theranostics

View full text Add to dashboard Cite

show abstract

“…Advances in deeper phenotyping of cell types with scRNA‐seq enable researchers to further characterize OA phenotypes, contributing to the discovery of targetable mediators or pathways 121 . In past decades, some of them are promising under clinical investigation in randomized controlled trials 122 . Emerging therapies such as disease‐modifying OA drugs (DMOADs) include those targeting ECM‐degrading, promoting structural repair, limiting local low‐grade inflammation and inhibiting multiple signalling pathways 123,124 .…”

Section: Discovering Targets For Osteoarthritismentioning

confidence: 99%

Single‐cell RNA sequencing in osteoarthritis

Gu,

Hu,

Zhang

et al. 2023

Cell Proliferation

Self Cite

View full text Add to dashboard Cite

Osteoarthritis is a progressive and heterogeneous joint disease with complex pathogenesis. The various phenotypes associated with each patient suggest that better subgrouping of tissues associated with genotypes in different phases of osteoarthritis may provide new insights into the onset and progression of the disease. Recently, single‐cell RNA sequencing was used to describe osteoarthritis pathogenesis on a high‐resolution view surpassing traditional technologies. Herein, this review summarizes the microstructural changes in articular cartilage, meniscus, synovium and subchondral bone that are mainly due to crosstalk amongst chondrocytes, osteoblasts, fibroblasts and endothelial cells during osteoarthritis progression. Next, we focus on the promising targets discovered by single‐cell RNA sequencing and its potential applications in target drugs and tissue engineering. Additionally, the limited amount of research on the evaluation of bone‐related biomaterials is reviewed. Based on the pre‐clinical findings, we elaborate on the potential clinical values of single‐cell RNA sequencing for the therapeutic strategies of osteoarthritis. Finally, a perspective on the future development of patient‐centred medicine for osteoarthritis therapy combining other single‐cell multi‐omics technologies is discussed. This review will provide new insights into osteoarthritis pathogenesis on a cellular level and the field of applications of single‐cell RNA sequencing in personalized therapeutics for osteoarthritis in the future.

show abstract

“…[4] As people live longer on average, the incidence of age-dependent bone-related diseases such as osteoporosis, arthritis, and neoplastic bone diseases is increasing, and treatments are becoming more sophisticated. [5,6] Osteoporosis is the most common bone metabolic disease. The incidence of osteoporosis in the United States is 15% in women between the ages of 50 and 59, and as high as 70% in women 80 and older.…”

Section: Introductionmentioning

confidence: 99%

Bone‐Targeted Exosomes: Strategies and Applications

Wang

Duan

Wang

et al. 2023

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

As the global population ages, bone-related diseases have increasingly become a major social problem threatening human health. Exosomes, as natural cell products, have been used to treat bone-related diseases due to their superior biocompatibility, biological barrier penetration, and therapeutic effects. Moreover, the modified exosomes exhibit strong bone-targeting capabilities that may improve efficacy and avoid systemic side effects, demonstrating promising translational potential. However, a review of bone-targeted exosomes is still lacking. Thus, the recently developed exosomes for bone-targeting applications in this review are focused. The biogenesis and bone-targeting regulatory functions of exosomes, the constructive strategies of modified exosomes to improve bone-targeting, and their therapeutic effects for bone-related diseases are introduced. By summarizing developments and challenges in bone-targeted exosomes, It is striven to shed light on the selection of exosome constructive strategies for different bone diseases and highlight their translational potential for future clinical orthopedics.

show abstract

Safety Evaluation of Natural Drugs in Chronic Skeletal Disorders: A Literature Review of Clinical Trials in the Past 20 years

Cited by 16 publications

References 65 publications

Targeted and responsive biomaterials in osteoarthritis

Targeted and responsive biomaterials in osteoarthritis

Single‐cell RNA sequencing in osteoarthritis

Bone‐Targeted Exosomes: Strategies and Applications

Contact Info

Product

Resources

About